SCOPUS 정보 검색 플랫폼

New England Journal of Medicine

Volumn 361, Issue 18, 2009, Pages 1717-1720

Lost in transmission - FDA drug information that never reaches clinicians

(2) Schwartz, Lisa M a Woloshin, Steven a

a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESZOPICLONE; PAMIDRONIC ACID; PLACEBO; RAMELTEON; ZOLEDRONIC ACID;

CHRONIC DISEASE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCALCEMIA; HYPERPROLACTINEMIA; INFORMATION DISSEMINATION; INSOMNIA; MEDICAL INFORMATION; NEPHROTOXICITY; PRIORITY JOURNAL; SHORT SURVEY;

ADVERTISING AS TOPIC; DRUG APPROVAL; DRUG LABELING; HUMANS; HYPNOTICS AND SEDATIVES; INFORMATION DISSEMINATION; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 71049184878 PISSN: 00284793 EISSN: 15334406 Source Type: Journal
DOI: 10.1056/NEJMp0907708 Document Type: Article

Times cited : (44)

References (5)

1
- 85031334215
- Silver Spring, MD: Food and Drug Administration. Accessed October 8, 2009, at
- Drugs@FDA. Approval history of NDA 021223: Zometa. Silver Spring, MD: Food and Drug Administration. (Accessed October 8, 2009, at http://www. accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist.)
- Approval History of NDA 021223: Zometa

2
- 0035863508
- Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
- Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567 (Pubitemid 32112871)
- (2001) Journal of Clinical Oncology , vol.19 , Issue.2 , pp. 558-567
- Major, P.¹ Lortholary, A.² Hon, J.³ Abdi, E.⁴ Mills, G.⁵ Menssen, H.D.⁶ Yunus, F.⁷ Bell, R.⁸ Body, J.⁹ Quebe-Fehling, E.¹⁰ Seaman, J.¹¹

3
- 85031344256
- Silver Spring, MD: Food and Drug Administration. Accessed October 8, 2009, at
- Drugs@FDA. Approval history of NDA 021476: Lunesta. Silver Spring, MD: Food and Drug Administration. (Accessed October 8, 2009, at http://www. accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist.)
- Approval History of NDA 021476: Lunesta

4
- 85031337940
- Silver Spring, MD: Food and Drug Administration. Accessed October 8, 2009, at
- Drugs@FDA. Approval history of NDA 021782: Rozerem. Silver Spring, MD: Food and Drug Administration. (Accessed October 8, 2009, at http://www. accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist.)
- Approval History of NDA 021782: Rozerem

5
- 65349165683
- Using a drug facts box to communicate drug benefits and harms: Two randomized trials
- Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 2009;150:516-527
- (2009) Ann Intern Med , vol.150 , pp. 516-527
- Schwartz, L.M.¹ Woloshin, S.² Welch, H.G.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.